Literature DB >> 21445973

Long-term exposure of gastrointestinal stromal tumor cells to sunitinib induces epigenetic silencing of the PTEN gene.

Jing Yang1, Takayuki Ikezoe, Chie Nishioka, Yuka Takezaki, Kazuhiro Hanazaki, Takahiro Taguchi, Akihito Yokoyama.   

Abstract

Although sunitinib possesses significant clinical effects on imatinib-resistant gastrointestinal stromal tumors (GISTs), the individuals with GIST eventually become resistant to treatment with this tyrosine kinase inhibitor. The mechanism of resistance to sunitinib is still under investigation. To address this issue, we have established sunitinib-resistant GIST-T1 sublines (designated as GIST-T1R) by culturing cells with increasing concentrations of sunitinib. GIST-T1R cells were also resistant to imatinib-mediated growth inhibition. Examination of intracellular signaling found that Akt/ mammalian target of rapamycin (mTOR) signaling remained activated in GIST-T1R but not in parental GIST-T1 cells, after exposure of these cells to sunitinib, as measured by immunoblotting. Further study found that the phosphatase and tensin homolog deleted on chromosome ten (PTEN) gene was silenced by methylation of the promoter region of the gene. Notably, forced-expression of PTEN in GIST-T1R cells negatively regulated the Akt/mTOR pathways and sensitized these cells to sunitinib-mediated growth arrest and apoptosis. Taken together, epigenetic silence of PTEN might be one of the mechanisms which cause drug-resistance in individuals with GIST after exposure to tyrosine kinase inhibitors. Blockade of the PI3K/Akt signaling with the specific inhibitors could be useful in such a case.
Copyright © 2011 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21445973     DOI: 10.1002/ijc.26095

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  25 in total

1.  Rho-kinase expression in Hirschsprung's disease.

Authors:  David Coyle; Anne Marie O'Donnell; Nicolae Corcionivoschi; John Gillick; Prem Puri
Journal:  Pediatr Surg Int       Date:  2015-08-15       Impact factor: 1.827

2.  The oncoprotein HBXIP uses two pathways to up-regulate S100A4 in promotion of growth and migration of breast cancer cells.

Authors:  Shuangping Liu; Leilei Li; Yingyi Zhang; Yiwen Zhang; Yu Zhao; Xiaona You; Zhenhua Lin; Xiaodong Zhang; Lihong Ye
Journal:  J Biol Chem       Date:  2012-06-27       Impact factor: 5.157

3.  Branched-chain amino acid-enriched nutrients stimulate antioxidant DNA repair in a rat model of liver injury induced by carbon tetrachloride.

Authors:  Kengo Ichikawa; Takehiro Okabayashi; Yasuo Shima; Tatsuo Iiyama; Yuka Takezaki; Masaya Munekage; Tsutomu Namikawa; Takeki Sugimoto; Michiya Kobayashi; Toshiki Mimura; Kazuhiro Hanazaki
Journal:  Mol Biol Rep       Date:  2012-10-09       Impact factor: 2.316

4.  miRNA-221 and miRNA-222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours.

Authors:  Michaela Angelika Ihle; Marcel Trautmann; Helen Kuenstlinger; Sebastian Huss; Carina Heydt; Jana Fassunke; Eva Wardelmann; Sebastian Bauer; Hans-Ulrich Schildhaus; Reinhard Buettner; Sabine Merkelbach-Bruse
Journal:  Mol Oncol       Date:  2015-04-10       Impact factor: 6.603

Review 5.  Molecular characterization and pathogenesis of gastrointestinal stromal tumor.

Authors:  Takeshi Niinuma; Hiromu Suzuki; Tamotsu Sugai
Journal:  Transl Gastroenterol Hepatol       Date:  2018-01-09

Review 6.  Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma.

Authors:  Adrián Mariño-Enríquez; Judith V M G Bovée
Journal:  Surg Pathol Clin       Date:  2016-09

7.  The green tea polyphenol EGCG potentiates the antiproliferative activity of sunitinib in human cancer cells.

Authors:  Yi Zhou; Jie Tang; Yang Du; Jing Ding; Ji-Yan Liu
Journal:  Tumour Biol       Date:  2016-01-05

8.  Epigenetics in gastrointestinal stromal tumors: clinical implications and potential therapeutic perspectives.

Authors:  Athanasios D Sioulas; Diamantina Vasilatou; Vasiliki Pappa; George Dimitriadis; Konstantinos Triantafyllou
Journal:  Dig Dis Sci       Date:  2013-07-20       Impact factor: 3.199

Review 9.  Exploring novel therapeutic targets in GIST: focus on the PI3K/Akt/mTOR pathway.

Authors:  Shreyaskumar Patel
Journal:  Curr Oncol Rep       Date:  2013-08       Impact factor: 5.075

10.  Activation of alternate prosurvival pathways accounts for acquired sunitinib resistance in U87MG glioma xenografts.

Authors:  Qingyu Zhou; Hua Lv; Amin R Mazloom; Huilei Xu; Avi Ma'ayan; James M Gallo
Journal:  J Pharmacol Exp Ther       Date:  2012-08-06       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.